BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 30702189)

  • 1. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
    Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
    Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
    Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
    Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
    Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
    Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
    Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
    Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Delivery of an Adenoviral Vector Carrying the
    Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
    Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A carrier-free multiplexed gene editing system applicable for suspension cells.
    Ju A; Lee SW; Lee YE; Han KC; Kim JC; Shin SC; Park HJ; EunKyeong Kim E; Hong S; Jang M
    Biomaterials; 2019 Oct; 217():119298. PubMed ID: 31280073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy.
    Wei S; Shao X; Liu Y; Xiong B; Cui P; Liu Z; Li Q
    J Mater Chem B; 2022 Feb; 10(8):1291-1300. PubMed ID: 35141737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
    Xu Y; Chen C; Guo Y; Hu S; Sun Z
    Front Immunol; 2022; 13():848327. PubMed ID: 35300341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
    Liao Y; Chen L; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
    Oncotarget; 2017 May; 8(18):30276-30287. PubMed ID: 28415820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells.
    Lin Y; Wilk U; Pöhmerer J; Hörterer E; Höhn M; Luo X; Mai H; Wagner E; Lächelt U
    Small; 2023 Jan; 19(2):e2205318. PubMed ID: 36399647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
    Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
    J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
    Zhen S; Lu J; Chen W; Zhao L; Li X
    Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.